EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Olfactory dysfunction and amyloid-positivity in Parkinson’s disease—longitudinal analysis of cognitive decline and cerebrospinal fluid markers

Victoria Larsson iD, Sara Hall, Kaj Blennow, Oskar Hansson

PLOS One · 2025

DOI: 10.1371/journal.pone.0325560 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Victoria Larsson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Parkinson Disease, Cognitive Dysfunction, Amyloid beta-Peptides, Olfaction Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Alzheimerfonden, Hjärnfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Olfactory dysfunction is a common non-motor symptom in Parkinson’s disease (PD). The objective was to evaluate the association between olfaction in PD with cross-sectional and longitudinal assessments of clinical variables and novel cerebrospinal fluid (CSF) markers.

Methods

Patients with PD and baseline olfactory function assessed using the Brief Smell Identification Test (B-SIT) were included from the BioFINDER-1 cohort. Clinical variables, CSF measures and disease status were assessed longitudinally for up to 11 years. CSF was analyzed using Roche Elecsys® NeuroToolKit, including biomarkers of neurodegeneration, glial activation, neuroinflammation and the core Alzheimer disease biomarkers.

Results

A total of 172 patients with PD were included, 63 with normal olfactory function and 109 with hyposmia. No differences were seen in clinical variables at baseline. Glial fibrillary acidic protein was the only CSF marker differing at baseline, being elevated in hyposmic patients with PD (12.25 ± 3.87 vs 10.46 ± 3.68, p = 0.001). At follow-up, olfactory function declined predominantly in patients with normal olfaction at baseline (β = −0.25 [−0.40 to −0.12], p = 0.001). Patients with PD with both olfactory dysfunction and amyloid-positivity (defined by the CSF Aβ42/Aβ40 ratio) declined faster in several cognitive and motor measures. Olfaction and amyloid-status were independently associated with increased risk of progressing to dementia (B-SIT score, HR = 0.77 [0.67–0.88] and amyloid-positivity, HR = 4.47 [2.30–8.67]).

Conclusions

Olfactory dysfunction and amyloid-positivity are independently associated with a higher rate of cognitive decline and progression to dementia in patients with PD. Novel CSF markers of neurodegeneration and glial-activity do not differ depending on olfactory status in PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseCognitive DysfunctionAmyloid beta-PeptidesOlfaction DisordersHumansMaleFemaleBiomarkersAgedLongitudinal StudiesMiddle AgedCross-Sectional StudiesGlial Fibrillary Acidic Protein

Substanzen

BiomarkersAmyloid beta-PeptidesGlial Fibrillary Acidic Protein

Autor:innen und Institutionen

  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
  • Skåne University Hospital, Department of Neurology and Rehabilitation Medicine, Lund, Sweden.
  • Memory Clinic, Skåne University Hospital, Malmö, Sweden.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.

ORCID-Profile: Victoria Larsson

Förderung

  • Vetenskapsrådet
  • Alzheimerfonden
  • Hjärnfonden
  • EU Joint Programme – Neurodegenerative Disease Research
  • Alzheimer's Association
  • Knut och Alice Wallenbergs Stiftelse
  • Parkinsonfonden
  • Skånes universitetssjukhus

Zitieren

APA

Larsson, V., Hall, S., Blennow, K., & Hansson, O. (2025). Olfactory dysfunction and amyloid-positivity in Parkinson’s disease—longitudinal analysis of cognitive decline and cerebrospinal fluid markers. PLOS One. https://doi.org/10.1371/journal.pone.0325560

Vancouver

Larsson V, Hall S, Blennow K, Hansson O. Olfactory dysfunction and amyloid-positivity in Parkinson’s disease—longitudinal analysis of cognitive decline and cerebrospinal fluid markers. PLOS One. 2025. doi:10.1371/journal.pone.0325560

BibTeX
@article{Larsson2025,
  author = {Larsson, Victoria and Hall, Sara and Blennow, Kaj and Hansson, Oskar},
  title = {Olfactory dysfunction and amyloid-positivity in Parkinson’s disease—longitudinal analysis of cognitive decline and cerebrospinal fluid markers},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325560}
}
Kostenlos starten →